Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    18662191 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Efficacy Study of Sodium Channel Blocker in LQT3 Patients
Condition: Long QT Syndrome
Interventions: Drug: Placebo;   Drug: Ranolazine
2 Recruiting Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine
Condition: Long QT Syndrome Type 3
Intervention: Drug: Ranolazine

Study has passed its completion date and status has not been verified in more than two years.